newsfilter
← Latest News
PR Newswire·

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

–Company initiates activities to resume dosing –Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 LEXINGTON, Mass., May 9, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clini